v3.25.2
Revenue - Disaggregation of Revenue by Product (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Disaggregation of Revenue [Line Items]        
Revenue $ 15,557.7 $ 11,302.8 $ 28,286.2 $ 20,070.8
U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 10,814.2 7,835.2 19,303.7 13,529.6
Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 4,743.4 3,467.5 8,982.5 6,541.2
Cardiometabolic Health        
Disaggregation of Revenue [Line Items]        
Revenue 11,342.9 7,514.6 20,551.0 13,007.6
Cardiometabolic Health | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 8,363.4 5,716.1 14,940.1 9,806.1
Cardiometabolic Health | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 2,979.5 1,798.5 5,610.9 3,201.6
Mounjaro        
Disaggregation of Revenue [Line Items]        
Revenue 5,198.9 3,090.8 9,040.7 4,897.4
Mounjaro | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 3,301.8 2,413.7 5,957.7 3,934.0
Mounjaro | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,897.1 677.2 3,083.0 963.4
Zepbound        
Disaggregation of Revenue [Line Items]        
Revenue 3,381.4 1,243.2 5,693.3 1,760.6
Zepbound | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 3,379.9 1,243.2 5,685.4 1,760.6
Zepbound | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1.5 0.0 7.9 0.0
Trulicity        
Disaggregation of Revenue [Line Items]        
Revenue 1,092.2 1,245.6 2,187.4 2,701.9
Trulicity | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 743.8 876.7 1,514.4 1,958.6
Trulicity | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 348.4 368.9 673.1 743.3
Jardiance        
Disaggregation of Revenue [Line Items]        
Revenue 690.0 769.6 1,704.3 1,456.1
Jardiance | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 382.2 428.9 692.0 797.1
Jardiance | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 307.8 340.7 1,012.4 659.0
Other cardiometabolic health        
Disaggregation of Revenue [Line Items]        
Revenue 980.4 1,165.4 1,925.3 2,191.6
Other cardiometabolic health | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 555.7 753.6 1,090.6 1,355.8
Other cardiometabolic health | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 424.7 411.7 834.5 835.9
Oncology        
Disaggregation of Revenue [Line Items]        
Revenue 2,413.6 2,158.7 4,361.1 3,968.7
Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 1,419.3 1,275.2 2,465.1 2,273.5
Oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 994.3 883.5 1,896.0 1,695.1
Verzenio        
Disaggregation of Revenue [Line Items]        
Revenue 1,489.3 1,331.9 2,648.2 2,382.2
Verzenio | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 929.0 861.4 1,586.6 1,499.6
Verzenio | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 560.3 470.5 1,061.5 882.6
Other oncology        
Disaggregation of Revenue [Line Items]        
Revenue 924.3 826.8 1,712.9 1,586.5
Other oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 490.3 413.8 878.5 773.9
Other oncology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 434.0 413.0 834.5 812.5
Immunology        
Disaggregation of Revenue [Line Items]        
Revenue 1,255.6 1,082.4 2,343.6 1,916.3
Immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 700.9 599.8 1,279.0 996.9
Immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 554.6 482.6 1,064.6 919.4
Taltz        
Disaggregation of Revenue [Line Items]        
Revenue 847.6 824.7 1,609.5 1,428.8
Taltz | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 548.8 539.4 1,025.3 886.4
Taltz | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 298.8 285.3 584.2 542.3
Other immunology        
Disaggregation of Revenue [Line Items]        
Revenue 408.0 257.7 734.1 487.5
Other immunology | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 152.1 60.4 253.7 110.5
Other immunology | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 255.8 197.3 480.4 377.1
Neuroscience        
Disaggregation of Revenue [Line Items]        
Revenue 344.0 339.5 616.1 728.6
Neuroscience | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 247.9 191.9 437.2 355.1
Neuroscience | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 96.1 147.6 178.9 373.5
Other        
Disaggregation of Revenue [Line Items]        
Revenue 201.5 207.6 414.4 449.6
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Revenue 82.7 52.2 182.2 98.0
Other | Outside U.S.        
Disaggregation of Revenue [Line Items]        
Revenue $ 118.9 $ 155.4 $ 232.2 $ 351.6